RU2699726C2 - Селективные ингибиторные пептиды nox-1 и их применение - Google Patents

Селективные ингибиторные пептиды nox-1 и их применение Download PDF

Info

Publication number
RU2699726C2
RU2699726C2 RU2015132087A RU2015132087A RU2699726C2 RU 2699726 C2 RU2699726 C2 RU 2699726C2 RU 2015132087 A RU2015132087 A RU 2015132087A RU 2015132087 A RU2015132087 A RU 2015132087A RU 2699726 C2 RU2699726 C2 RU 2699726C2
Authority
RU
Russia
Prior art keywords
seq
peptide
skin
nox1
disease
Prior art date
Application number
RU2015132087A
Other languages
English (en)
Russian (ru)
Other versions
RU2015132087A (ru
Inventor
Хамид Реза РЕЗВАНИ
Фредерик Мазюрье
Ален ТЕЕБ
Л'Эмира Жида АРФУШЕ
Original Assignee
Юниверсите Де Бордо
Энсэрм
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47458818&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2699726(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Юниверсите Де Бордо, Энсэрм filed Critical Юниверсите Де Бордо
Publication of RU2015132087A publication Critical patent/RU2015132087A/ru
Application granted granted Critical
Publication of RU2699726C2 publication Critical patent/RU2699726C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y106/00—Oxidoreductases acting on NADH or NADPH (1.6)
    • C12Y106/03—Oxidoreductases acting on NADH or NADPH (1.6) with oxygen as acceptor (1.6.3)
    • C12Y106/03001—NAD(P)H oxidase (1.6.3.1), i.e. NOX1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Birds (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
RU2015132087A 2013-01-03 2014-01-03 Селективные ингибиторные пептиды nox-1 и их применение RU2699726C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13150187.6A EP2752196A1 (en) 2013-01-03 2013-01-03 Selective nox-1 inhibitor peptides and uses thereof
EP13150187.6 2013-01-03
PCT/EP2014/050063 WO2014106649A1 (en) 2013-01-03 2014-01-03 Selective nox-1 inhibitor peptides and uses thereof

Publications (2)

Publication Number Publication Date
RU2015132087A RU2015132087A (ru) 2017-02-06
RU2699726C2 true RU2699726C2 (ru) 2019-09-09

Family

ID=47458818

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015132087A RU2699726C2 (ru) 2013-01-03 2014-01-03 Селективные ингибиторные пептиды nox-1 и их применение

Country Status (14)

Country Link
US (2) US20170000842A9 (enExample)
EP (2) EP2752196A1 (enExample)
JP (1) JP6488237B2 (enExample)
CN (1) CN105007933A (enExample)
AU (1) AU2014204309B2 (enExample)
BR (1) BR112015015242B1 (enExample)
CA (1) CA2894576A1 (enExample)
DK (1) DK2941268T3 (enExample)
HU (1) HUE050715T2 (enExample)
IL (1) IL239762B (enExample)
MA (1) MA38296B2 (enExample)
RU (1) RU2699726C2 (enExample)
TN (1) TN2015000295A1 (enExample)
WO (1) WO2014106649A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3034500A1 (en) 2014-12-17 2016-06-22 Genkyotex Sa Amido thiazole derivatives as NADPH oxidase inhibitors
JP6472693B2 (ja) * 2015-03-24 2019-02-20 株式会社荏原製作所 基板処理装置
US20170110622A1 (en) * 2015-10-14 2017-04-20 Solarcity Corporation Apparatus for electroplating of electrodes on photovoltaic structures
WO2019023263A1 (en) * 2017-07-25 2019-01-31 Immune Pharmaceuticals, Inc. METHODS AND COMPOSITIONS FOR TREATING TUMORS COMPRISING A BCR-ABL1 FUSION GENE
EP3628669A1 (en) 2018-09-28 2020-04-01 GenKyoTex Suisse SA Novel compounds as nadph oxidase inhibitors
SG11202102674RA (en) * 2018-10-05 2021-04-29 Pfizer Boron containing pde4 inhibitors
AU2020289560A1 (en) 2019-06-05 2021-12-23 Emory University Peptidomimetics for the treatment of coronavirus and picornavirus infections
KR20210129517A (ko) * 2020-04-20 2021-10-28 경북대학교병원 Nadph 산화효소 1 저해제를 유효성분으로 포함하는 허혈-재관류 손상 예방 또는 치료용 조성물
CN113773394B (zh) * 2020-06-10 2023-10-27 山东大学 一种融合肽及在制备抗肿瘤制剂中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024419A1 (en) * 1994-03-11 1995-09-14 Ariad Pharmaceuticals, Inc. Methods and materials for identifying inhibitors of molecular interactions mediated by sh3 domains
WO1997030074A1 (en) * 1996-02-16 1997-08-21 Cytogen Corporation Isolation and use of sh3 binding peptides
EA201001558A1 (ru) * 2008-03-28 2011-06-30 Ню Скин Интернэшнл, Инк. КОМПОЗИЦИИ, СОДЕРЖАЩИЕ anr NOX-ИНГИБИТОРЫ ДЛЯ ПОДАВЛЕНИЯ АКТИВНЫХ ФОРМ КИСЛОРОДА

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593966A (en) * 1989-03-31 1997-01-14 The United States Of America As Represented By The Department Of Health And Human Services Peptide derivatives of cytochrome b558 and their use as medicaments
US5726155A (en) * 1993-08-02 1998-03-10 The Scripps Research Institute Regulation of oxidative burst using LMWG-derived peptides and analogs
GB2285047B (en) * 1993-12-21 1998-04-15 Yamanouchi U K Ltd Polypeptides which inhibit the NADPH oxidase complex
JP4215274B2 (ja) * 1994-07-22 2009-01-28 ザ ユニバーシティー オブ ノースカロライナ アット チャペル ヒル Ｓｒｃ ＳＨ３結合性ペプチドとその分離法と利用法
US6713605B1 (en) * 1996-04-10 2004-03-30 Kansas State University Research Foundation Synthetic peptides that inhibit leukocyte superoxide anion production and/or attract leukocytes
US6551795B1 (en) * 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
JP2005168329A (ja) * 2003-12-08 2005-06-30 Hokkaido Univ Ｎａｄｐｈオキシダーゼ活性を阻害するポリペプチド
US7582606B2 (en) * 2005-11-03 2009-09-01 The Board Of Regents Of The University Of Texas System Nadph oxidase cytosolic cofactor mutant
US20100119533A1 (en) * 2007-03-07 2010-05-13 Cornelius Joseph Clancy Polynucleotides and Polypeptides Identified by IVIAT Screening and Methods of Use
WO2013074816A2 (en) 2011-11-15 2013-05-23 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Novel inhibitors of nox1

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024419A1 (en) * 1994-03-11 1995-09-14 Ariad Pharmaceuticals, Inc. Methods and materials for identifying inhibitors of molecular interactions mediated by sh3 domains
WO1997030074A1 (en) * 1996-02-16 1997-08-21 Cytogen Corporation Isolation and use of sh3 binding peptides
EA201001558A1 (ru) * 2008-03-28 2011-06-30 Ню Скин Интернэшнл, Инк. КОМПОЗИЦИИ, СОДЕРЖАЩИЕ anr NOX-ИНГИБИТОРЫ ДЛЯ ПОДАВЛЕНИЯ АКТИВНЫХ ФОРМ КИСЛОРОДА

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VALENTE A.J. et al., 2007, NOX1 NADPH oxidase regulation by the NOXA1 SH3 domain, Free Radic Biol Med., 2007, v.43,n.3,p.384-396. *

Also Published As

Publication number Publication date
HUE050715T2 (hu) 2021-01-28
IL239762B (en) 2020-04-30
EP2752196A1 (en) 2014-07-09
EP2941268B1 (en) 2020-06-24
US20170000842A9 (en) 2017-01-05
EP2941268A1 (en) 2015-11-11
US10517919B2 (en) 2019-12-31
IL239762A0 (en) 2015-08-31
JP2016505612A (ja) 2016-02-25
US20160030503A1 (en) 2016-02-04
JP6488237B2 (ja) 2019-03-20
AU2014204309A1 (en) 2015-07-09
CN105007933A (zh) 2015-10-28
AU2014204309B2 (en) 2018-03-01
CA2894576A1 (en) 2014-07-10
US20170340697A1 (en) 2017-11-30
MA38296B2 (fr) 2019-10-31
RU2015132087A (ru) 2017-02-06
WO2014106649A1 (en) 2014-07-10
TN2015000295A1 (en) 2016-10-03
BR112015015242B1 (pt) 2020-10-27
DK2941268T3 (da) 2020-09-28

Similar Documents

Publication Publication Date Title
RU2699726C2 (ru) Селективные ингибиторные пептиды nox-1 и их применение
US9926350B2 (en) Targeting of chondroitin sulfate glycans
RU2722449C2 (ru) Полилигандные лекарственные конъюгаты и их применения
CN109513010B (zh) 肿瘤细胞特异性响应的自组装药物纳米缀合物
US9422340B2 (en) Macrocyclic compounds useful as inhibitors of histone deacetylases
EP2509421B1 (en) Drug delivery of temozolomide for systemic based treatment of cancer
KR101363455B1 (ko) 매트릭스 메탈로프로테아제 활성 억제 펩타이드 및 이의 용도
Shankar et al. Cathepsin B degradable star-shaped peptidic macromolecules for delivery of 2-methoxyestradiol
Lu et al. Synthesis of lipoic acid–peptide conjugates and their effect on collagen and melanogenesis
EP3970801A1 (en) Ras inhibitory peptide
US20220017538A1 (en) Thioester prodrugs of macrocycles as inhibitors of histone deacetylases
ES2773964T3 (es) Polipéptidos para el tratamiento de cáncer
Josan et al. Solid-phase synthetic strategy and bioevaluation of a labeled δ-opioid receptor ligand Dmt-Tic-Lys for in vivo imaging
WO2012080705A1 (en) Imaging agents
CN109862903A (zh) 治疗性sall4肽
Li et al. A mitochondria-targeted idebenone derivative W1a mitigates cerebral ischemia-reperfusion injury by preserving mitochondrial integrity and suppressing neuroinflammation
WO2022133540A1 (en) Cyclic peptides and uses thereof
CA2944318A1 (en) Compositions and methods for the treatment of platinum-drug resistant cancer

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20181108

FZ9A Application not withdrawn (correction of the notice of withdrawal)

Effective date: 20190611

MM4A The patent is invalid due to non-payment of fees

Effective date: 20210104